In addition, consistent with our results, a recent proteomic study, based on iTRAQ labeling and ESI–MS/MS, showed a decrease in Hpt level of patients suffering from moderate and severe MR compared to non-MR patients [37]. This evidence concerns the gene MRS2 and miotic rate.